This episode features Dr Rachel Grisham and Dr Kathleen Moore discussing the historical challenges associated with treating low-grade serous ovarian cancer and the recent transformational approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC.

Learn about the emerging role of CDH6-targeting antibody–drug conjugates for ovarian cancer with Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard MD, PhD, discussing the latest results and implications of studies evaluating raludotatug deruxtecan and other agents.

In this podcast, Dr David Miller and Dr Vishal Patel discuss advances in the management of cutaneous squamous cell carcinoma (cSCC), exploring how neoadjuvant and adjuvant immunotherapy is transforming treatment paradigms and highlighting patient selection, toxicity management, and emerging strategies to improve patient care.

Listen to expert hematologists provide an up-to-date clinical overview of paroxysmal nocturnal hemoglobinuria (PNH), exploring its pathogenesis, clinical manifestations, and the evolution of complement-based therapies.

Listen to Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patients.

Listen to Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients.

Listen to Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss the new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer.

Listen to Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. Hear their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma.

Listen in as 3 oncology experts discuss the care of patients with metastatic pancreatic cancer, including patient symptomatology, treatment selection considerations, and emerging novel therapies that are showing promise in this setting.

Listen to Dr Brad Kahl and Dr Noopur Raje discuss the latest advances in CAR T-cell therapy for lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.

Listen to Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address key questions on the use of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer treatment. The discussion covers genomic testing options, adjuvant treatment duration, toxicity management topics, and how the available clinical data and updated guidelines influence therapeutic decisions.

Listen to Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the diagnosis, prognosis, and current limited treatment options for poorly differentiated extrapulmonary neuroendocrine carcinomas, followed by a discussion focusing on emerging DLL3-targeted therapies, including bispecific therapies, antibody–drug conjugates, and CAR T-cell therapies, and their potential roles in improving patient outcomes.

Listen to this podcast with clinical and managed care pharmacy expert perspectives on the use of available and emerging subcutaneous immunotherapy options for patients with cancer

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, discuss their thoughts on a few of the most impactful studies in lymphomas and acute lymphoblastic leukemia (ALL) from the EHA and ICML 2025 congresses.

In this podcast, experts discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting.

Audio podcast with expert insights and takeaways from a large educational program on available and emerging first-line treatment options for HER2-positive metastatic breast cancer.

In this episode, Eytan M. Stein, MD, and Eunice S. Wang, MD, explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP explore the latest key clinical updates on BTK inhibitors in CLL, featuring insights from the randomized phase III FLAIR, SEQUOIA, and BRUIN CLL-321 trials presented at ASCO and EHA 2025. This episode unpacks evolving treatment strategies, MRD-guided approaches, and what these developments mean for oncology professionals.

Listen to this audio podcast with expert insights and overview of the latest data for immune checkpoint inhibitors for advanced or metastatic hepatocellular carcinoma (HCC), for intermediate HCC in combination with TACE, and the latest guidelines for high-risk early HCC.

In this podcast, experts discuss the latest frontline treatment options for advanced Hodgkin lymphoma and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients.